# Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer

> **NCT03562897** · PHASE2 · COMPLETED · sponsor: **Catalysis SL** · enrollment: 40 (actual)

## Conditions studied

- Carcinoma
- Ovarian Neoplasm
- Endocrine Gland Neoplasm
- Urogenital Neoplasms
- Ovarian Diseases
- Adnexal Diseases
- Genital Diseases, Female
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Endocrine System Diseases
- Gonadal Disorders
- Genital Neoplasm, Female
- Neoplasms, Glandular and Epithelial

## Interventions

- **DIETARY_SUPPLEMENT:** Ocoxin-Viusid

## Key facts

- **NCT ID:** NCT03562897
- **Lead sponsor:** Catalysis SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-25
- **Primary completion:** 2022-02-15
- **Final completion:** 2022-06-15
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03562897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03562897, "Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03562897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*